As previously stated, adults with AD had increased frequencies of IL-22 production by TCD4 cells [17], and the role of IL-22 in AD pathogenesis could be demonstrated in a clinical trial using a neutralizing anti-IL-22 antibody that could induce progressive and sustained clinical improvements in adult AD patients [19]. Here, IL22 is linked to Alzheimer disease.